Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration

Thorarinn J. Sigurdsson, Earl Fu, Dimitris N. Tatakis, Michael D. Rohrer, Ulf M E Wikesjö

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Recombinant human bone morphogenetic protein-2 (rhBMP-2) induced bone regeneration and osseointegration was evaluated in supraalveolar peri-implant defects in 5 beagle dogs. Alveolar bone was reduced 5 mm in height in mandibular premolar areas and the premolars were extracted. Three 10 mm titanium fixtures were placed 5 mm into each reduced alveolar crest, leaving 5 mm in a supraalveolar position. Alternate quadrants in consecutive animals received a surgical implant consisting of 2 ml rhBMP-2 (0.43 mg/ml) in a type I bovine collagen carrier, or the carrier alone (control). Fixtures and surgical implants were submerged under the gingival flaps. The healing interval was 16 weeks. Histometric and radiographic evaluations were made. Defect height averaged (±SD) 5.3±0.2 and 5.1±0.2 mm for rhBMP-2 and control defects, respectively (P>0.05, n=5, paired, t-test) Bone regeneration (height) averaged 4.2±1.0 and 0.5±0.3 mm for rhBMP-2 and control defects, respectively (P<0.05). Bone regeneration (area) averaged 6.1±6.3 and 0.2±0.2 mm2 for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within the confines of the defect averaged 19.1±10.1% and 8.2±4.6% for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within regenerated bone averaged 29.1±9.8% and 65.3±15.3% for rhBMP-2 and control defects, respectively (P<0.05). Osseointegration within the retained alveolar bone averaged 67.1±4.6% and 68.1±3.6% for rhBMP-2 and control defects, respectively (P>0.05). The results suggest that there is a potential for rhBMP-2 induced bone regeneration and osseointegration in surgical peri-implant defects.

Original languageEnglish (US)
Pages (from-to)367-374
Number of pages8
JournalClinical Oral Implants Research
Volume8
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Osseointegration
Bone Morphogenetic Protein 2
Bone Regeneration
Bicuspid
Bone and Bones
Collagen Type I
recombinant human bone morphogenetic protein-2
Titanium
Dogs

Keywords

  • Bone regeneration
  • Dental implants
  • Osseointegration rhBMP-2

ASJC Scopus subject areas

  • Oral Surgery

Cite this

Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. / Sigurdsson, Thorarinn J.; Fu, Earl; Tatakis, Dimitris N.; Rohrer, Michael D.; Wikesjö, Ulf M E.

In: Clinical Oral Implants Research, Vol. 8, No. 5, 01.01.1997, p. 367-374.

Research output: Contribution to journalArticle

Sigurdsson, Thorarinn J. ; Fu, Earl ; Tatakis, Dimitris N. ; Rohrer, Michael D. ; Wikesjö, Ulf M E. / Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. In: Clinical Oral Implants Research. 1997 ; Vol. 8, No. 5. pp. 367-374.
@article{907994cb8942441eb0067b577d13c860,
title = "Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration",
abstract = "Recombinant human bone morphogenetic protein-2 (rhBMP-2) induced bone regeneration and osseointegration was evaluated in supraalveolar peri-implant defects in 5 beagle dogs. Alveolar bone was reduced 5 mm in height in mandibular premolar areas and the premolars were extracted. Three 10 mm titanium fixtures were placed 5 mm into each reduced alveolar crest, leaving 5 mm in a supraalveolar position. Alternate quadrants in consecutive animals received a surgical implant consisting of 2 ml rhBMP-2 (0.43 mg/ml) in a type I bovine collagen carrier, or the carrier alone (control). Fixtures and surgical implants were submerged under the gingival flaps. The healing interval was 16 weeks. Histometric and radiographic evaluations were made. Defect height averaged (±SD) 5.3±0.2 and 5.1±0.2 mm for rhBMP-2 and control defects, respectively (P>0.05, n=5, paired, t-test) Bone regeneration (height) averaged 4.2±1.0 and 0.5±0.3 mm for rhBMP-2 and control defects, respectively (P<0.05). Bone regeneration (area) averaged 6.1±6.3 and 0.2±0.2 mm2 for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within the confines of the defect averaged 19.1±10.1{\%} and 8.2±4.6{\%} for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within regenerated bone averaged 29.1±9.8{\%} and 65.3±15.3{\%} for rhBMP-2 and control defects, respectively (P<0.05). Osseointegration within the retained alveolar bone averaged 67.1±4.6{\%} and 68.1±3.6{\%} for rhBMP-2 and control defects, respectively (P>0.05). The results suggest that there is a potential for rhBMP-2 induced bone regeneration and osseointegration in surgical peri-implant defects.",
keywords = "Bone regeneration, Dental implants, Osseointegration rhBMP-2",
author = "Sigurdsson, {Thorarinn J.} and Earl Fu and Tatakis, {Dimitris N.} and Rohrer, {Michael D.} and Wikesj{\"o}, {Ulf M E}",
year = "1997",
month = "1",
day = "1",
doi = "10.1034/j.1600-0501.1997.080503.x",
language = "English (US)",
volume = "8",
pages = "367--374",
journal = "Clinical Oral Implants Research",
issn = "0905-7161",
publisher = "Blackwell Munksgaard",
number = "5",

}

TY - JOUR

T1 - Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration

AU - Sigurdsson, Thorarinn J.

AU - Fu, Earl

AU - Tatakis, Dimitris N.

AU - Rohrer, Michael D.

AU - Wikesjö, Ulf M E

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Recombinant human bone morphogenetic protein-2 (rhBMP-2) induced bone regeneration and osseointegration was evaluated in supraalveolar peri-implant defects in 5 beagle dogs. Alveolar bone was reduced 5 mm in height in mandibular premolar areas and the premolars were extracted. Three 10 mm titanium fixtures were placed 5 mm into each reduced alveolar crest, leaving 5 mm in a supraalveolar position. Alternate quadrants in consecutive animals received a surgical implant consisting of 2 ml rhBMP-2 (0.43 mg/ml) in a type I bovine collagen carrier, or the carrier alone (control). Fixtures and surgical implants were submerged under the gingival flaps. The healing interval was 16 weeks. Histometric and radiographic evaluations were made. Defect height averaged (±SD) 5.3±0.2 and 5.1±0.2 mm for rhBMP-2 and control defects, respectively (P>0.05, n=5, paired, t-test) Bone regeneration (height) averaged 4.2±1.0 and 0.5±0.3 mm for rhBMP-2 and control defects, respectively (P<0.05). Bone regeneration (area) averaged 6.1±6.3 and 0.2±0.2 mm2 for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within the confines of the defect averaged 19.1±10.1% and 8.2±4.6% for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within regenerated bone averaged 29.1±9.8% and 65.3±15.3% for rhBMP-2 and control defects, respectively (P<0.05). Osseointegration within the retained alveolar bone averaged 67.1±4.6% and 68.1±3.6% for rhBMP-2 and control defects, respectively (P>0.05). The results suggest that there is a potential for rhBMP-2 induced bone regeneration and osseointegration in surgical peri-implant defects.

AB - Recombinant human bone morphogenetic protein-2 (rhBMP-2) induced bone regeneration and osseointegration was evaluated in supraalveolar peri-implant defects in 5 beagle dogs. Alveolar bone was reduced 5 mm in height in mandibular premolar areas and the premolars were extracted. Three 10 mm titanium fixtures were placed 5 mm into each reduced alveolar crest, leaving 5 mm in a supraalveolar position. Alternate quadrants in consecutive animals received a surgical implant consisting of 2 ml rhBMP-2 (0.43 mg/ml) in a type I bovine collagen carrier, or the carrier alone (control). Fixtures and surgical implants were submerged under the gingival flaps. The healing interval was 16 weeks. Histometric and radiographic evaluations were made. Defect height averaged (±SD) 5.3±0.2 and 5.1±0.2 mm for rhBMP-2 and control defects, respectively (P>0.05, n=5, paired, t-test) Bone regeneration (height) averaged 4.2±1.0 and 0.5±0.3 mm for rhBMP-2 and control defects, respectively (P<0.05). Bone regeneration (area) averaged 6.1±6.3 and 0.2±0.2 mm2 for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within the confines of the defect averaged 19.1±10.1% and 8.2±4.6% for rhBMP-2 and control defects, respectively (P>0.05). Osseointegration within regenerated bone averaged 29.1±9.8% and 65.3±15.3% for rhBMP-2 and control defects, respectively (P<0.05). Osseointegration within the retained alveolar bone averaged 67.1±4.6% and 68.1±3.6% for rhBMP-2 and control defects, respectively (P>0.05). The results suggest that there is a potential for rhBMP-2 induced bone regeneration and osseointegration in surgical peri-implant defects.

KW - Bone regeneration

KW - Dental implants

KW - Osseointegration rhBMP-2

UR - http://www.scopus.com/inward/record.url?scp=0031241928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031241928&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0501.1997.080503.x

DO - 10.1034/j.1600-0501.1997.080503.x

M3 - Article

C2 - 9612141

AN - SCOPUS:0031241928

VL - 8

SP - 367

EP - 374

JO - Clinical Oral Implants Research

JF - Clinical Oral Implants Research

SN - 0905-7161

IS - 5

ER -